指南与共识中医内科中药与中成药合理使用

榄香烯注射液辅助铂类化疗治疗III/IV期非小细胞肺癌的Meta分析

Elemene injection as adjunctive treatment to platinum-based chemotherapy in patients with stage III/IV non-small cell lung cancer: A meta-analysis following the PRISMA guidelines.
指南 / 共识 · Phytomedicine · 2018-12-10

该系统评价与Meta分析遵循PRISMA指南,纳入15项RCT共1410例III/IV期NSCLC患者,比较榄香烯注射液联合铂类化疗与单纯铂类化疗。结果显示联合治疗可提高疾病控制率、客观缓解率、1年和2年生存率、生活质量及细胞免疫功能,并减少严重毒性反应。

要点

  • 榄香烯注射液联合铂类化疗可提高III/IV期NSCLC患者的疾病控制率和客观缓解率。
  • 联合治疗可改善1年和2年生存率、生活质量及CD4+T细胞计数和CD4+/CD8+比值。
  • 联合治疗可减少严重毒性反应,但纳入研究的方法学质量多为低至中等。

核心结论

  • 榄香烯注射液是III/IV期非小细胞肺癌患者铂类化疗的安全有效的辅助治疗。
  • 榄香烯注射液可提高临床疗效、增强细胞免疫功能并减轻化疗毒性。
  • 需要高质量、报告显著生存结局和更长随访的RCT进一步证实结果。

研究设计与样本

  • 系统评价与Meta分析,遵循PRISMA指南,纳入15项随机对照试验共1410例III/IV期NSCLC患者。
  • 纳入比较榄香烯注射液联合铂类化疗与单纯铂类化疗的RCT,主要终点为疾病控制率(DCR)。

主要发现

  • 与单纯铂类化疗相比,联合治疗提高DCR(RR=1.23,95%CI 1.16至1.31,p<0.00001)。
  • 联合治疗提高ORR(RR=1.62,95%CI 1.44至1.82,p<0.00001)。
  • 联合治疗提高1年生存率(RR=1.33,95%CI 1.11至1.59,p=0.002)和2年生存率(RR=1.73,95%CI 1.21至2.46,p=0.002)。
  • 联合治疗改善生活质量(RR=1.91,95%CI 1.58至2.32,p<0.00001)。
  • 联合治疗提高CD4+T细胞计数(WMD=10.43,95%CI 8.25至12.62,p<0.00001)和CD4+/CD8+比值(WMD=0.78,95%CI 0.42至1.14,p<0.0001),并减少58%的严重毒性(RR=0.42,95%CI 0.34至0.52,p<0.00001)。

关键数值与推荐

  • 疾病控制率(DCR)为主要终点,客观缓解率(ORR)、生存率、生活质量、细胞免疫功能和毒性为次要结局。

临床怎么用

  • 对于III/IV期NSCLC患者,可考虑在铂类化疗基础上加用榄香烯注射液以改善疗效、免疫功能和减轻毒性。
  • 临床决策时应结合患者具体情况,并注意现有证据的方法学质量多为低至中等。

局限性

  • 纳入的大多数试验方法学质量低至中等。
  • 需要高质量、报告显著生存结局和更长随访的RCT进一步证实结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Elemene injection is an anticancer Chinese patent medicine that is widely used for the treatment of advanced lung cancer. Its active ingredients are β-, γ- and δ-elemene, which are extracted from Curcumaaromatica Salisb. (Curcumawenyujin Y.H. Chen & C. Ling). PURPOSE: To evaluate the effects of Elemene injection as adjunctive treatment to platinum-based chemotherapy (PBC) in patients with stage III/IV non-small cell lung cancer. STUDY DESIGN: A systematic review and meta-analysis of randomized clinical trials (RCTs). MATERIALS AND METHODS: A systematic review and meta-analysis were conducted following the PRISMA (Preferred Reported Items for Systematic Review and Meta-analysis) guidelines. Analyses were performed using Review Manager 5.3, Comprehensive Meta-Analysis 3.0 and Trial Sequential Analysis software. All RCTs comparing Elemene injection combined with PBC vs. PBC alone were selected and assessed for inclusion. The disease control rate (DCR) was defined as the primary endpoint, and the objective Response rate (ORR), survival rate, quality of life (QOL), cellular immune function and toxicities were the secondary outcomes. RESULTS: 15 RCTs recruiting 1,410 patients with stage III/IV NSCLC were included. The methodological quality of most included trials was low to moderate. Compared with PBC alone, Elemene injection plus PBC can improve DCR (RR = 1.23, 95% CI 1.16 to 1.31, p < 0.00001), ORR (RR = 1.62, 95% CI 1.44 to 1.82, p < 0.00001), 1- and 2-year survival rates (RR = 1.33, 95% CI 1.11 to 1.59, p = 0.002; RR = 1.73, 95% CI 1.21 to 2.46, p = 0.002, respectively), QOL (RR = 1.91, 95% CI 1.58 to 2.32, p < 0.00001), CD4+T cell counts (WMD = 10.43, 95% CI 8.25 to 12.62, p < 0.00001), and the CD4+/CD8+ratio (WMD = 0.78, 95% CI 0.42 to 1.14, p < 0.0001) and can reduce severe toxicities by 58% (RR = 0.42, 95% CI 0.34 to 0.52, p < 0.00001). CONCLUSION: Elemene injection is a safe and effective adjunctive treatment to platinum-based chemotherapy in patients with stage III/IV NSCLC. Elemene injection can improve clinical efficacy, enhance cellular immune function and alleviate the toxicity of chemotherapy. High-quality RCTs with significant survival outcomes and longer follow-ups are warranted to confirm the results further.

来源:Phytomedicine,查看原文。版权归原作者所有。

引用

  1. Wang X, Liu Z, Sui X, et al. Elemene injection as adjunctive treatment to platinum-based chemotherapy in patients with stage III/IV non-small cell lung cancer: A meta-analysis following the PRISMA guidelines. Phytomedicine. 2018. PMID: 31005810. doi:10.1016/j.phymed.2018.12.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。